Sikander Ailawadhi

61PUBLICATIONS
237CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (61)

|May 07, 2026
A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.

|Mar 30, 2026
Management of hematological toxicities after BCMA-directed CAR-T cell therapy.

Joselle Cook, Supriya Gupta, Nadine Abdallah

|Dec 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

Kenneth J C Lim, Melinda Tan, Ricardo Parrondo

|Aug 12, 2025
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.

Taxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl

|Jun 03, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Sikander Ailawadhi, Ivan Špička, Andrew Spencer

|May 23, 2025
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.

Ricardo D Parrondo, Saurav Das, Hanna Sledge

Pageof 11

Frequent Collaborators

19 joint publications

Ricardo Parrondo

14 joint publications

Morie Gertz

14 joint publications

Shaji Kumar

11 joint publications

Prashant Kapoor